Gout risk in adults with pre-diabetes initiating metformin (2024)

1. http://orcid.org/0000-0001-9157-4269Javier Marrugo1,2,3,
2. http://orcid.org/0000-0001-8951-2296Leah M Santacroce1,
3. http://orcid.org/0000-0002-8361-0650Misti L Paudel1,3,
4. http://orcid.org/0000-0002-3082-1374Sho f*ckui1,3,
5. http://orcid.org/0000-0002-8609-564XAlexander Turchin3,4,
6. http://orcid.org/0000-0001-9475-1363Sara K Tedeschi1,3,
7. http://orcid.org/0000-0001-8202-5428Daniel H Solomon3,5

1. ¹Department of Medicine, Division of Rheumatology Immunology and Allergy Research, Brigham and Women's Hospital, Boston, Massachusetts, USA
2. ²Department of Medicine, Division of Rheumatology, University of Sherbrooke and Centre Intégré Universitaire de Santé et de Services Sociaux de l’Estrie-CIUSSSE-CHUS, Sherbrooke, QC, Canada
3. ³Harvard Medical School, Boston, Massachusetts, USA
4. ⁴Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Boston, Massachusetts, USA
5. ⁵Department of Medicine, Division of Pharmacoepidemiology, Division of Rheumatology Immunology and Allergy Research, Brigham and Women's Hospital, Boston, Massachusetts, USA

1. Correspondence to Dr Javier Marrugo, Department of Medicine, Brigham and Women's Hospital Division of Rheumatology Immunology and Allergy Research, Boston, Massachusetts, USA; javiermarrugo{at}hms.harvard.edu; Professor Daniel H Solomon; dsolomon{at}bwh.harvard.edu

• Gout
• Incidence
• Crystal arthropathies

• Gout
• Incidence
• Crystal arthropathies

Footnotes

• Handling editor Josef S Smolen

• Contributors JM and DHS contributed to the original conception and design of this study. JM conducted the data analyses with supervision from DHS, MLP and SKT, which AT, LMS and SF reviewed. JM, DHS, SKT, SF, MLP, AT and LMS interpreted the data. JM prepared the original draft of the manuscript, which was critically reviewed by all other authors. All authors approved the final version after being involved in drafting and revising the article for important intellectual content. The corresponding authors (JM and DHS) attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. JM and DHS serve as the guarantors of this manuscript.

• Funding This work was supported by the National Institutes of Health (NIH-NIAMS P30AR072577). Source of funding had no role in the study design or execution, data interpretation or writing of the manuscript.

• Competing interests Disclosure of interests: DHS receives salary support from unrelated research contracts to Brigham and Women’s Hospital from CorEvitas, Janssen and Novartis. AT receives salary support from unrelated research contracts to Brigham and Women’s Hospital from Eli Lilly. AT serves as a consultant in areas unrelated to this research to Novo Nordisk and Proteomics International. SKT reports consulting fees from Novartis. JM: None declared. SF: None declared. MLP: None declared. LMS: None declared.

• Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.